Form 8-K - Current report:
SEC Accession No. 0001140361-23-029740
Filing Date
2023-06-14
Accepted
2023-06-14 06:02:15
Documents
13
Period of Report
2023-06-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20054419_8k.htm   iXBRL 8-K 29607
2 EXHIBIT 99.1 brhc20054419_ex99-1.htm EX-99.1 28986
  Complete submission text file 0001140361-23-029740.txt   204916

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pdsb-20230614.xsd EX-101.SCH 3871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pdsb-20230614_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pdsb-20230614_pre.xml EX-101.PRE 16048
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc20054419_8k_htm.xml XML 4412
Mailing Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932
Business Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932 800-208-3343
PDS Biotechnology Corp (Filer) CIK: 0001472091 (see all company filings)

IRS No.: 264231384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37568 | Film No.: 231012935
SIC: 2834 Pharmaceutical Preparations